Video

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

Alexander N. Shoushtari, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the rationale for the ​phase 3 CheckMate-067 trial in advanced melanoma.

​The ​landmark CheckMate-067 trial ​randomized patients with previously untreated, advanced melanoma 1:1:1 to receive nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by nivolumab, nivolumab plus ipilimumab-matched placebo, or ipilimumab plus nivolumab-matched placebo.

During the time of the study, ipilimumab ​monotherapy was considered the standard of care​, says Shoushtari. ​However, nivolumab and pembrolizumab (Keytruda) ​have since become new standards in the space.

As such, the ​study evaluated whether the addition of ipilimumab to nivolumab was superior to nivolumab alone, Shoushtari concludes.

Related Videos
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD